REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Research/Paper
Back to Research Library
PubMedClinical Trial

Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial.

Pant Shubham, Wainberg Zev A, Weekes Colin D, Furqan Muhammad, Kasi Pashtoon M, Devoe Craig E, Leal Alexis D, Chung Vincent, Basturk Olca, VanWyk Haley
Nature medicine2024DOI: 10.1038/s41591-023-02760-3

Citations

0

Subjects

Non-Human

Study Context

This clinical trial followed a structured protocol to evaluate safety and efficacy outcomes. The controlled methodology adds rigor and reproducibility to the reported results.

What This Study Type Means

  • Structured protocols ensure consistent methodology
  • Controlled conditions reduce confounding variables
  • Results inform the design of future human trials
  • Safety and toxicity data guide regulatory decisions

Evidence Reliability: Moderate — controlled trials add rigor, but non-human data requires validation

How to Interpret This Research

1

Look for the sample size — larger studies produce more reliable results. Single-digit sample sizes warrant caution.

2

Check whether the study was funded by a pharmaceutical company or conducted independently, as funding sources can influence study design and reporting.

3

Examine the primary endpoint — did the study measure what actually matters clinically, or a proxy marker?

4

Statistical significance (p < 0.05) does not always mean clinical significance. Look at the actual effect size.

5

Always consult a qualified healthcare provider before making treatment decisions based on research findings. Published research is not a substitute for personalized medical advice.

Citation

Pant Shubham, Wainberg Zev A, Weekes Colin D et al.. (2024). Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial.. Nature medicine. https://doi.org/10.1038/s41591-023-02760-3

View full text on PubMed

Related Papers

Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.

Mendias Christopher L et al.· Sports medicine (Auckland, N.Z.)· 2026Review

From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management.

Yuan Claire et al.· International journal of molecular sciences· 2026Review

Carbonless amino acids and a carbonless GHK peptide.

Skurski Piotr et al.· Physical chemistry chemical physics : PCCP· 2026Review

The GHK-Cu delays aging in Caenorhabditis elegans via coordinated regulation of mitochondrial function and activation of DAF-16/SKN-1 pathways.

Wen Huijun et al.· Biogerontology· 2026Review

Glycyl-L-histidyl-L-lysine-Cu2

Hu Jing et al.· European journal of pharmacology· 2026Review

Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.

Mayfield Cory K et al.· The American journal of sports medicine· 2026Review

Explore Further

Research Library

Browse all indexed papers

Research Guides

Plain-language peptide guides

This content is derived from peer-reviewed research for educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide-based therapy.